Screener
ArriVent BioPharma, Inc. AVBP Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock $0.0001 par value, 200,000,000 shares authorized; 45,308,941 and 42,452,251 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 4 |
| Additional paid-in capital | 772,206 | 711,847 |
| Accumulated deficit | (447,961) | (404,641) |
| Accumulated other comprehensive income (loss) | (270) | 14 |
| Total stockholders’ equity | 323,980 | 307,224 |
| Total liabilities and stockholders’ equity | $349,295 | $333,169 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s retained earnings?
- ArriVent BioPharma, Inc. (AVBP) reported retained earnings of -$447.96M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s retained earnings changed year-over-year?
- ArriVent BioPharma, Inc.'s retained earnings decreased by 48.0% year-over-year, from -$302.72M to -$447.96M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s retained earnings?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s retained earnings has grown at a 60.1% compound annual growth rate (CAGR), from -$157.85M to -$404.64M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about ArriVent BioPharma, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude